|
| |
Image Results
Loading...
Loading...
Celgene Pharmaceuticals Co-promote Pages on BioPortfolio:
Results from other life science and pharmaceutical sites:
Acceleron Pharma Announces Global Collaboration with Celgene on ...
20 Feb 2008 ... The companies will co-promote the products in North America. Acceleron will receive tiered royalties on worldwide net sales. “Celgene ...
http://www.biospace.com/news_story.aspx?NewsEntityId=86623...
|
News: Celgene Signs On to Advance Acceleron's Bone Loss Programs ...
20 Feb 2008 ... Celgene agreed to help Acceleron Pharma advance some of its bone loss ... The companies will copromote the products in North America. ...
http://www.genengnews.com/news/bnitem.aspx?name=30784081...
|
New Report Just Published: World Multiple Myeloma Therapeutics ...
Company profiles are mostly extracted from URL research and reported select online ... of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals, ... Myeloma II-39 Takeda Gains FDA Approval to Promote Velcade II-40 Health ...
http://www.prnewswire.com/news-releases/new-report-just-publ...
|
News: MethylGene to Stop Backing Clinical Program in Collaboration ...
19 Sep 2008 ... Instead Celgene will assume 100% of the program costs for its licensed ... original transaction to codevelop and copromote subsequent compounds, ... An agreement with Taiho Pharmaceutical, which covers MGCD0103 and its ...
http://www.genengnews.com/news/bnitem.aspx?name=42108388...
|
{1}'s REVLIMID(TM) Receives Orphan Drug Designation From The ...
Orphan drug status is granted by the EC to promote development of drugs to treat ... Celgene's lead Immunomodulatory drug, REVLIMID has received orphan drug and ... is an integrated global pharmaceutical company engaged primarily in the ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1533752...
|
Acceleron, Celgene in Potential $1.8B Bone Loss - BioWorld Today
Celgene also will have the right to develop ACE-011, as well as the ... Another key factor was to retain co-promotion rights to ACE-011 in North America. ...
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher...
|
Off To A Running Start -- Celgene - News, Search Jobs, Events
Biotech and Pharmaceutical News & Jobs. Search the Site ... At the same time, the company plans to launch two Phase III trials in 5q- and non-5q- low risk MDS ... and an oncology label, which allows for oncology marketing and promotion. ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1984722...
|
Ligand Pharmaceuticals Announces Third Quarter Results - Yahoo ...
5 Nov 2009 ... SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) (the ... including Bristol-Myers Squibb, Celgene, Cephalon, .... Current portion of co-promote termination liability, 11925, 10958 ...
http://biz.yahoo.com/bw/091105/20091105006461.html?.v=1...
|
Attention Deficit Syndrome - BioSpace offers Pharmaceutical ...
Fujisawa Pharmaceutical Co., Ltd. And Carlsson Research AB Conclude ... Celgene Corporation (CELG) Release: Focalin XR(TM) Clinical Studies Suggest ...
http://www.biospace.com/news_by_disease_results.aspx?TheRxId...
|
Summary of CELGENE CORP /DE/ - Yahoo! Finance
30 Oct 2009 ... Celgene Corporation and its subsidiaries (collectively "we" or "our") is a global integrated biopharmaceutical company primarily engaged in ...
http://biz.yahoo.com/e/091030/celg10-q.html...
|
|